Indivior Pharmaceuticals, Inc 6-K, filed Jun 27, 2023
Indivior Pharmaceuticals, Inc. (INDV)
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on June 27, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: June 27, 2023
Commission File Number: 001-37835
Indivior PLC
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXHIBIT INDEX
| Exhibit No. |
Description of Exhibit | |
| 99.1 | Announcement sent to the London Stock Exchange on June 27, 2023, titled “Indivior to Announce Q2 and H1 2023 Results on July 27th”. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | ||||||
| Date: June 27, 2023 | /s/ Kathryn Hudson | |||||
| Name: Kathryn Hudson | ||||||
| Title: Company Secretary | ||||||
Exhibit 99.1
Indivior to Announce Q2 and H1 2023 Results on July 27th
Slough, UK, and Richmond, VA, June 27, 2023 – Indivior PLC (LSE/NASDAQ: INDV) today announced that it will release its Q2 and H1 2023 results on July 27th at 7:00 a.m. London time (2:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange’s Regulatory News Service (RNS) and on the “Investors” section of the company’s website at www.indivior.com.
Mark Crossley, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 1:00 p.m. London time (8:00 a.m. U.S. Eastern) on July 27th.
Access to the Live Webcast Presentation
The webcast event and materials can be accessed on the “Investors” section of the company’s website at www.indivior.com before the event begins.
The webcast link: https://edge.media-server.com/mmc/p/z4yh2znf
Participants may access the presentation telephonically by registering with the following link:
https://register.vevent.com/register/BI80255ae130d847e3944c2584e201ae3e
(Registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
A replay of the presentation will be available at www.indivior.com.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
Contact:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com
###